These AV-EVLPs can inhibit pancreatic cancer progression by increasing mitochondrial ROS release through the activation of caspase-1/3/7/9 and GSDMD/E-mediated pyroptosis in Panc-1 cells. Here, GSDMD is linked to familial pancreatic carcinoma.